– Eli Lilly has announced a global commercialization agreement to integrate Dexcom’s continuous glucose monitoring (CGM) devices into Lilly’s personalized diabetes management system.
– The personalized diabetes management system, currently in development to advance the treatment of diabetes, will integrate connected insulin delivery devices, software and analysis to equip people with diabetes and their healthcare providers with personalized information and guidance to help them better manage their diabetes.
– If approved, the system will include both pen- and pump-based platforms.
Eli Lilly and Company has announced a global commercialization agreement to integrate DexCom, Inc. products into Lilly’s personalized diabetes management system, currently in development to advance the treatment of diabetes. Under the terms of the non-exclusive agreement, Lilly will use Dexcom’s continuous glucose monitoring (CGM) devices in both the pen- and pump-based platforms of the system being designed to help improve diabetes management.
Impact of Diabetes in the U.S.
Approximately 30 million Americans1 and an estimated 425 million adults worldwide have diabetes. Type 2 diabetes is the most common type internationally, accounting for an estimated 90 to 95 percent of all diabetes cases in The United States alone. Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.
“CGMs provide people with diabetes and their healthcare team with important real-time data that can help alleviate the burden of diabetes management, including overall glucose level trends and information on time spent in target blood glucose range,” said Rick Doubleday, executive vice president and chief commercial officer of Dexcom. “We’re looking forward to expanding our collaboration with Lilly as we integrate our technology into their system and believe it will help reduce some of the complexity that can come from managing diabetes every day.”
Integration Details
The agreement with Dexcom builds on Lilly’s efforts to provide a comprehensive system that integrates connected insulin delivery devices, software, and analysis to equip people with type 1 and type 2 diabetes and their healthcare providers with personalized information and guidance to help simplify the management of their diabetes.
The personalized diabetes management system being developed will include both pen- and pump-based platforms. The goal of the pen-based platform is to integrate personalized data from a prefilled, disposable insulin pen with data from glucose-sensing technologies into a compatible software application. Personalized data is transferred from the pen via an optional attachment. The goal of the pump-based platform, which is a hybrid closed loop system, is to use integrated devices – an insulin pump, a continuous glucose monitor and a dedicated handheld controller or smartphone application that controls the system – to automate insulin dosing.
Why It Matters
“Even with all of the advances in diabetes technology, insulin therapy is still overwhelming and complex,” said Mike Mason, senior vice president, Connected Care and Insulins, Lilly Diabetes. “We’re excited to include Dexcom’s technology in the solutions we deliver to people with diabetes to help improve health outcomes by delivering actionable insights in one connected system. As we integrate our expertise and insights with those from our partners, like Dexcom, we are aiming to not only transform the way we develop and deliver medicine, but to transform how people manage their diabetes.”
